{"id":"https://openalex.org/W2019650137","doi":"https://doi.org/10.1016/j.neuropharm.2011.02.026","title":"5-HT4 receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment","display_name":"5-HT4 receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment","publication_year":2011,"publication_date":"2011-03-09","ids":{"openalex":"https://openalex.org/W2019650137","doi":"https://doi.org/10.1016/j.neuropharm.2011.02.026","mag":"2019650137","pmid":"https://pubmed.ncbi.nlm.nih.gov/21392515"},"language":"en","primary_location":{"id":"doi:10.1016/j.neuropharm.2011.02.026","doi":"https://doi.org/10.1016/j.neuropharm.2011.02.026","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.neuropharm.2011.02.026","pdf_url":null,"source":{"id":"https://openalex.org/S160566677","display_name":"Neuropharmacology","issn_l":"0028-3908","issn":["0028-3908","1873-7064"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-3","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuropharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Fei Shen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210133216","display_name":"Theravance Biopharma (United States)","ror":"https://ror.org/03a6z4w08","country_code":"US","type":"company","lineage":["https://openalex.org/I4210133216"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Fei Shen","raw_affiliation_strings":["Department of Pharmacology, Theravance Inc., 901 Gateway Boulevard, South San Francisco, CA 94080, USA. fshen@theravance.com","Department of Pharmacology, Theravance Inc., 901 Gateway Boulevard, South San Francisco, CA 94080, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacology, Theravance Inc., 901 Gateway Boulevard, South San Francisco, CA 94080, USA. fshen@theravance.com","institution_ids":["https://openalex.org/I4210133216"]},{"raw_affiliation_string":"Department of Pharmacology, Theravance Inc., 901 Gateway Boulevard, South San Francisco, CA 94080, USA","institution_ids":["https://openalex.org/I4210133216"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027330002","display_name":"Jacqueline A.M. Smith","orcid":"https://orcid.org/0000-0001-5028-8725","observed_orcids":["https://orcid.org/0000-0001-5028-8725"]},"institutions":[{"id":"https://openalex.org/I4210133216","display_name":"Theravance Biopharma (United States)","ror":"https://ror.org/03a6z4w08","country_code":"US","type":"company","lineage":["https://openalex.org/I4210133216"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jacqueline A.M. Smith","raw_affiliation_strings":["Department of Molecular and Cell Biology, Theravance Inc., 901 Gateway Boulevard, South San Francisco, CA 94080, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Molecular and Cell Biology, Theravance Inc., 901 Gateway Boulevard, South San Francisco, CA 94080, USA","institution_ids":["https://openalex.org/I4210133216"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047726469","display_name":"Ray Chang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210133216","display_name":"Theravance Biopharma (United States)","ror":"https://ror.org/03a6z4w08","country_code":"US","type":"company","lineage":["https://openalex.org/I4210133216"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ray Chang","raw_affiliation_strings":["Department of Molecular and Cell Biology, Theravance Inc., 901 Gateway Boulevard, South San Francisco, CA 94080, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Molecular and Cell Biology, Theravance Inc., 901 Gateway Boulevard, South San Francisco, CA 94080, USA","institution_ids":["https://openalex.org/I4210133216"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027600676","display_name":"David L. Bourdet","orcid":"https://orcid.org/0000-0001-6220-1922","observed_orcids":["https://orcid.org/0000-0001-6220-1922"]},"institutions":[{"id":"https://openalex.org/I4210133216","display_name":"Theravance Biopharma (United States)","ror":"https://ror.org/03a6z4w08","country_code":"US","type":"company","lineage":["https://openalex.org/I4210133216"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David L. Bourdet","raw_affiliation_strings":["Department of Drug Metabolism and Pharmacokinetics, Theravance Inc., 901 Gateway Boulevard, South San Francisco, CA 94080, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Drug Metabolism and Pharmacokinetics, Theravance Inc., 901 Gateway Boulevard, South San Francisco, CA 94080, USA","institution_ids":["https://openalex.org/I4210133216"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066233381","display_name":"Pamela R. Tsuruda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210133216","display_name":"Theravance Biopharma (United States)","ror":"https://ror.org/03a6z4w08","country_code":"US","type":"company","lineage":["https://openalex.org/I4210133216"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pamela R. Tsuruda","raw_affiliation_strings":["Department of Molecular and Cell Biology, Theravance Inc., 901 Gateway Boulevard, South San Francisco, CA 94080, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Molecular and Cell Biology, Theravance Inc., 901 Gateway Boulevard, South San Francisco, CA 94080, USA","institution_ids":["https://openalex.org/I4210133216"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076249708","display_name":"Glenmar P. Obedencio","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210133216","display_name":"Theravance Biopharma (United States)","ror":"https://ror.org/03a6z4w08","country_code":"US","type":"company","lineage":["https://openalex.org/I4210133216"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Glenmar P. Obedencio","raw_affiliation_strings":["Department of Drug Metabolism and Pharmacokinetics, Theravance Inc., 901 Gateway Boulevard, South San Francisco, CA 94080, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Drug Metabolism and Pharmacokinetics, Theravance Inc., 901 Gateway Boulevard, South San Francisco, CA 94080, USA","institution_ids":["https://openalex.org/I4210133216"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5066889736","display_name":"David T. Beattie","orcid":"https://orcid.org/0009-0004-8548-9980","observed_orcids":["https://orcid.org/0009-0004-8548-9980"]},"institutions":[{"id":"https://openalex.org/I4210133216","display_name":"Theravance Biopharma (United States)","ror":"https://ror.org/03a6z4w08","country_code":"US","type":"company","lineage":["https://openalex.org/I4210133216"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David T. Beattie","raw_affiliation_strings":["Department of Pharmacology, Theravance Inc., 901 Gateway Boulevard, South San Francisco, CA 94080, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacology, Theravance Inc., 901 Gateway Boulevard, South San Francisco, CA 94080, USA","institution_ids":["https://openalex.org/I4210133216"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210133216"],"apc_list":{"value":4300,"currency":"USD","value_usd":4300},"apc_paid":null,"fwci":4.0323,"has_fulltext":false,"cited_by_count":83,"citation_normalized_percentile":{"value":0.94871938,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"61","issue":"1-2","first_page":"69","last_page":"79"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","score":0.0020000000949949026,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alzheimer-s-disease","display_name":"Alzheimer's disease","score":0.9929999709129333},{"id":"https://openalex.org/keywords/cognitive-enhancement","display_name":"cognitive enhancement","score":0.5809999704360962},{"id":"https://openalex.org/keywords/app-processing","display_name":"APP processing","score":0.9760000109672546},{"id":"https://openalex.org/keywords/sappalpha","display_name":"sAPP\u03b1","score":0.8970000147819519},{"id":"https://openalex.org/keywords/amyloid-beta","display_name":"amyloid-beta","score":0.9760000109672546},{"id":"https://openalex.org/keywords/camp-accumulation","display_name":"cAMP accumulation","score":0.7080000042915344},{"id":"https://openalex.org/keywords/scopolamine-induced-cognitive-deficits","display_name":"scopolamine-induced cognitive deficits","score":0.777999997138977},{"id":"https://openalex.org/keywords/donepezil","display_name":"donepezil","score":0.6570000052452087},{"id":"https://openalex.org/keywords/acetylcholinesterase-inhibitors","display_name":"acetylcholinesterase inhibitors","score":0.8669999837875366},{"id":"https://openalex.org/keywords/central-nervous-system-penetration","display_name":"CNS penetration","score":0.6919999718666077},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8069999814033508}],"concepts":[{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.8362047672271729},{"id":"https://openalex.org/C44752575","wikidata":"https://www.wikidata.org/wiki/Q1417562","display_name":"Morris water navigation task","level":3,"score":0.6941279172897339},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.615945041179657},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.5650259256362915},{"id":"https://openalex.org/C58732023","wikidata":"https://www.wikidata.org/wiki/Q770260","display_name":"Partial agonist","level":4,"score":0.5480088591575623},{"id":"https://openalex.org/C31705614","wikidata":"https://www.wikidata.org/wiki/Q423510","display_name":"Amyloid precursor protein","level":4,"score":0.5284637808799744},{"id":"https://openalex.org/C22885893","wikidata":"https://www.wikidata.org/wiki/Q4862743","display_name":"Cholinergic","level":2,"score":0.5199036002159119},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4807688891887665},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.4453241229057312},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.43394702672958374},{"id":"https://openalex.org/C38533456","wikidata":"https://www.wikidata.org/wiki/Q1671589","display_name":"Intrinsic activity","level":4,"score":0.4301983118057251},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4266929626464844},{"id":"https://openalex.org/C502032728","wikidata":"https://www.wikidata.org/wiki/Q11081","display_name":"Alzheimer's disease","level":3,"score":0.33057546615600586},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.28820979595184326},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.24000906944274902},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.07344269752502441},{"id":"https://openalex.org/C2781161787","wikidata":"https://www.wikidata.org/wiki/Q48360","display_name":"Hippocampus","level":2,"score":0.04631209373474121},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003071","descriptor_name":"Cognition","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D003071","descriptor_name":"Cognition","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006168","descriptor_name":"Guinea Pigs","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011485","descriptor_name":"Protein Binding","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D016564","descriptor_name":"Amyloid beta-Protein Precursor","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D017207","descriptor_name":"Rats, Sprague-Dawley","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D044422","descriptor_name":"Receptors, Serotonin, 5-HT4","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":true},{"descriptor_ui":"D046188","descriptor_name":"Protein Modification, Translational","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D046188","descriptor_name":"Protein Modification, Translational","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":true},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D057809","descriptor_name":"HEK293 Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058828","descriptor_name":"Serotonin 5-HT4 Receptor Agonists","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D058828","descriptor_name":"Serotonin 5-HT4 Receptor Agonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.neuropharm.2011.02.026","doi":"https://doi.org/10.1016/j.neuropharm.2011.02.026","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.neuropharm.2011.02.026","pdf_url":null,"source":{"id":"https://openalex.org/S160566677","display_name":"Neuropharmacology","issn_l":"0028-3908","issn":["0028-3908","1873-7064"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-3","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuropharmacology","raw_type":"journal-article"},{"id":"pmid:21392515","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21392515","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuropharmacology","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":58,"referenced_works":["https://openalex.org/W1518851833","https://openalex.org/W1570135279","https://openalex.org/W1895538680","https://openalex.org/W1956258389","https://openalex.org/W1965961744","https://openalex.org/W1966632119","https://openalex.org/W1971454022","https://openalex.org/W1978530682","https://openalex.org/W1979376962","https://openalex.org/W1981405948","https://openalex.org/W1994693522","https://openalex.org/W2003306914","https://openalex.org/W2007133271","https://openalex.org/W2007654265","https://openalex.org/W2007789566","https://openalex.org/W2009418154","https://openalex.org/W2010150387","https://openalex.org/W2012862746","https://openalex.org/W2017831981","https://openalex.org/W2017836262","https://openalex.org/W2022549388","https://openalex.org/W2022722753","https://openalex.org/W2023688161","https://openalex.org/W2028638859","https://openalex.org/W2030902457","https://openalex.org/W2033592766","https://openalex.org/W2033848049","https://openalex.org/W2033955782","https://openalex.org/W2037991163","https://openalex.org/W2043972017","https://openalex.org/W2049890856","https://openalex.org/W2057323598","https://openalex.org/W2058724927","https://openalex.org/W2059089835","https://openalex.org/W2064402334","https://openalex.org/W2071593047","https://openalex.org/W2072826498","https://openalex.org/W2074631079","https://openalex.org/W2076147139","https://openalex.org/W2078548800","https://openalex.org/W2078852369","https://openalex.org/W2084177228","https://openalex.org/W2085568943","https://openalex.org/W2090663050","https://openalex.org/W2093366809","https://openalex.org/W2099128415","https://openalex.org/W2108141803","https://openalex.org/W2112893277","https://openalex.org/W2121786183","https://openalex.org/W2122692162","https://openalex.org/W2123262275","https://openalex.org/W2151984407","https://openalex.org/W2154787902","https://openalex.org/W2155462253","https://openalex.org/W2162512841","https://openalex.org/W2170892449","https://openalex.org/W2334352131","https://openalex.org/W4249375539"],"related_works":["https://openalex.org/W2088358969","https://openalex.org/W2340392887","https://openalex.org/W7095476696","https://openalex.org/W1979376962","https://openalex.org/W4237039954","https://openalex.org/W1518851833","https://openalex.org/W2151984407","https://openalex.org/W2012717818","https://openalex.org/W2750299285","https://openalex.org/W1963490345"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":8},{"year":2020,"cited_by_count":8},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":14},{"year":2013,"cited_by_count":9},{"year":2012,"cited_by_count":6}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}